Abstract:MiR‐31 expression is elevated during BRAFV600E‐assocaited PTC. MiR‐31 mediates BRAFV600E‐induced PTC development and dedifferentiation in genetic mouse model. MiR‐31 facilitates Wnt/β‐catenin signaling via repressing tumor suppressors CEBPA and DACH1. Nanoparticles‐carried anti‐miR‐31 antagomirs elevate radio‐sensitivity of BRAFV600E‐induced PTC tumors to 131I therapy, efficiently suppress tumor growth. Background BRAFV600E is the most common genetic mutation in differentiated thyroid cancer (DTC) occurring in 60% of patients and drives malignant tumour cell phenotypes including proliferation, metastasis and immune‐escape. BRAFV600E‐mutated papillary thyroid cancer (PTC) also displays greatly reduced expression of thyroid differentiation markers, thus tendency to radioactive iodine (RAI) refractory and poor prognosis. Therefore, understanding the molecular mechanisms and main oncogenic events underlying BRAFV600E will guide future therapy development. Methods Bioinformatics and clinical specimen analyses, genetic manipulation of BRAFV600E‐induced PTC model, functional and mechanism exploration guided with transcriptomic screening, as well as systematic rescue experiments were applied to investigate miR‐31 function within BRAFV600E‐induced thyroid cancer development. Besides, nanoparticles carrying miR‐31 antagomirs were testified to alleviate 131I iodide therapy on PTC models. Results We identify miR‐31 as a significantly increased onco‐miR in BRAFV600E‐associated PTC that promotes tumour progression, metastasis and RAI refractoriness via sustained Wnt/β‐catenin signalling. Mechanistically, highly activated BRAF/MAPK pathway induces miR‐31 expression via c‐Jun‐mediated transcriptional regulation across in vitro and transgenic mouse models. MiR‐31 in turn facilitates β‐catenin stabilisation via directly repressing tumour suppressors CEBPA and DACH1, which direct the expression of multiple essential Wnt/β‐catenin pathway inhibitors. Genetic functional assays showed that thyroid‐specific knockout of miR‐31 inhibited BRAFV600E‐induced PTC progression, and strikingly, enhanced expression of sodium‐iodide symporter and other thyroid differentiation markers, thus promoted 131I uptake. Nanoparticle‐mediated application of anti‐miR‐31 antagomirs markedly elevated radio‐sensitivity of BRAFV600E‐induced PTC tumours to 131I therapy, and efficiently suppressed tumour progression in the pre‐clinical mouse model. Conclusions Our findings elucidate a novel BRAF/MAPK‐miR‐31‐Wnt/β‐catenin regulatory mechanism underlying clinically BRAFV600E‐associated DTC tumourigenesis and dedifferentiation, also highlight a potential adjuvant therapeutic strategy for advanced DTC.

Proteostatic reactivation of the developmental transcription factor TBX3 drives BRAF/MAPK-mediated tumorigenesis

TBX2 controls a proproliferative gene expression program in melanoma

Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors

Taz Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and is Inhibited by the Hippo Pathway

Tgfbr2 inactivation facilitates cellular plasticity and development of Pten-null prostate cancer

c-Myc is Required for BRAF(V600E)-Induced Epigenetic Silencing by H3K27me3 in Tumorigenesis.

Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance

Usp1-Wdr48 Deubiquitinase Complex Enhances Tgf-Beta Induced Epithelial-Mesenchymal Transition Of Tnbc Cells Via Stabilizing Tak1

ERK-mediated Phosphorylation Regulates SOX10 Sumoylation and Targets Expression in Mutant BRAF Melanoma

Lys63-linked polyubiquitination of BRAF at lysine 578 is required for BRAF-mediated signaling

Abstract LB208: An intricate connection between canonical Wnt and MAPK/ERK signaling drives the partial hybrid EMT state involving FOXC2/p63 activation leading to cancer stemness and metastasis

USP1-WDR48 deubiquitinase complex enhances TGF-β induced epithelial–mesenchymal transition of TNBC cells via stabilizing TAK1

Synergistic Activation of Mutant TERT Promoter by Sp1 and GABPA in BRAFV600E-driven Human Cancers

Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade.

A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma

The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function.

Targeting miR‐31 represses tumourigenesis and dedifferentiation of BRAFV600E‐associated thyroid carcinoma

The Map3k13-Trim25-Fbxw7 Alpha Axis Affects C-Myc Protein Stability And Tumor Development

Data from The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function

Enhancer Reprogramming within Pre-existing Topologically Associated Domains Promotes TGF-β-Induced EMT and Cancer Metastasis

TERT Accelerates BRAF Mutant-Induced Thyroid Cancer Dedifferentiation and Progression by Regulating Ribosome Biogenesis